Patents by Inventor Michael Ochse

Michael Ochse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS
    Publication number: 20220169620
    Abstract: The present invention is directed to spiro-cyclic amine derivatives which are modulators of S1P receptors and are useful in the treatment of CNS disorders.
    Type: Application
    Filed: November 30, 2021
    Publication date: June 2, 2022
    Inventors: Willie Amberg, Gisela Backfisch, Karen Bodié, Katja Hempel, Loic Laplanche, Mario Mezler, Michael Ochse, Sean Turner, Jeroen van Bergeijk, Elizabeth van der Kam
  • EXTRACORPOREAL BLOOD TREATMENT MACHINE COMPRISING A POKA-YOKE FOR A PRESSURE SENSOR
    Publication number: 20220152285
    Abstract: An extracorporeal blood treatment machine includes a blood treatment device, a conveying device for conveying blood through the blood treatment device, and a connection mask designed to interchangeably receive a tube set in a predefined arrangement. The tube set has pressure-monitoring lines that branch off from the tube set and can be connected to pressure sensor connections located on the connection mask. The pressure sensor connections are spaced apart and positioned so as to match the tube set such that, when the tube set is mounted in the predefined arrangement on the connection mask, each pressure-monitoring line, owing to its limited length and the predefined arrangement of the associated branch on the blood treatment machine, can be connected exclusively to only one of the pressure sensor connections. A corresponding tube set is used with the extracorporeal blood treatment machine.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 19, 2022
    Inventors: Sebastian Broegger, Michael Ochse, Kai-Uwe Ritter, Thorsten Thomas
  • 1,2,3,4-SUBSTITUTED QUINOLINE COMPOUNDS AS SIP MODULATORS
    Publication number: 20210147381
    Abstract: The invention relates to 1,2,3,4-substituted quinoline compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: July 16, 2018
    Publication date: May 20, 2021
    Inventors: Wilhelm AMBERG, Hervé GENESTE, Wilfried HORNBERGER, Udo LANGE, Mario MEZLER, Michael OCHSE, Frank OELLIEN, Sean C. TURNER, Jeroen VAN BERGEIJK, Elizabeth VAN DER KAM
  • SPIRO-COMPOUNDS AS SIP MODULATORS
    Publication number: 20200055817
    Abstract: The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Inventors: Wilhelm AMBERG, Jeroen VAN BERGEIJK, Herve GENESTE, Wilfried HORNBERGER, Elizabeth Louise VAN DER KAM, Udo LANGE, Mario MEZLER, Michael OCHSE, Frank OELLIEN, Patrick WALLESER, Sean C. TURNER
  • Fused heterocyclic compounds as S1P modulators
    Patent number: 10556907
    Abstract: The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: February 11, 2020
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Udo Lange, Michael Ochse, Elizabeth van der Kam, Jeroen van Bergeijk, Sean Turner, Frank Oellien, Patrick Walleser, Wilhelm Amberg, Wilfried Hornberger, Herve Geneste, Mario Mezler, Charles Hutchins
  • Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use
    Patent number: 10556914
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 11, 2020
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Jürgen Dinges, Achim Moeller, Michael Ochse, Martin Schmidt, Michael Schulz, Sean Turner, Elizabeth Louise Van Der Kam, Anil Vasudevan
  • SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE
    Publication number: 20190367531
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: May 10, 2019
    Publication date: December 5, 2019
    Inventors: Jürgen DINGES, Achim MOELLER, Michael OCHSE, Martin SCHMIDT, Michael SCHULZ, Sean TURNER, Elizabeth Louise VAN DER KAM, Anil VASUDEVAN
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 10308610
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: June 4, 2019
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Fused (hetero)cyclic compounds as S1P modulators
    Patent number: 10280159
    Abstract: The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: May 7, 2019
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilhelm Amberg, Udo Lange, Herve Geneste, Michael Ochse, Ralf Biesinger, Frank Oellien
  • Substituted pyrazolopyrimidines and method of use
    Patent number: 10155770
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: December 18, 2018
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Ramin Faghih, Achim Moeller, Michael Ochse, Frauke Pohlki, Martin Schmidt, Kevin Sippy, Sean Turner, Elizabeth Louise Van Der Kam
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20180222905
    Abstract: The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Katja Jantos
  • SUBSTITUTED PYRAZOLOPYRIMIDINES AND METHOD OF USE
    Publication number: 20180105530
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: October 25, 2017
    Publication date: April 19, 2018
    Inventors: Ramin FAGHIH, Achim MOELLER, Michael OCHSE, Frauke POHLKI, Martin SCHMIDT, Kevin SIPPY, Sean TURNER, Elizabeth Louise VAN DER KAM
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20180099936
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9938269
    Abstract: The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: April 10, 2018
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Katja Jantos
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20180030033
    Abstract: The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: October 4, 2017
    Publication date: February 1, 2018
    Inventors: Hervé GENESTE, Sean Colm TURNER, Michael OCHSE, Karla DRESCHER, Lawrence A. BLACK, Katja JANTOS
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9856220
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: January 2, 2018
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Substituted pyrazolopyrimidines and method of use
    Patent number: 9828381
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the ?-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: November 28, 2017
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Ramin Faghih, Achim Moeller, Michael Ochse, Frauke Pohlki, Martin Schmidt, Kevin Sippy, Sean Turner, Elizabeth Louise Van Der Kam
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9790203
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: October 17, 2017
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Hervé Geneste, Sean Colm Turner, Michael Ochse, Karla Drescher, Lawrence A. Black, Katja Jantos
  • FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS
    Publication number: 20170174672
    Abstract: The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 22, 2017
    Inventors: Wilhelm Amberg, Udo Lange, Herve Geneste, Michael Ochse, Ralf Biesinger, Frank Oellien
  • Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors
    Patent number: 9657034
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: May 23, 2017
    Assignees: AbbVie Deuschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Sean Turner, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Lawrence Black, Katja Jantos